Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions

Hongtao Liu, Elizabeth S. Rich, Lucy Godley, Olatoyosi Odenike, Loren Joseph, Susana Marino, Justin Kline, Vu Nguyen, John Cunningham, Richard A. Larson, Paula del Cerro, Linda Schroeder, Lisa Pape, Wendy Stock, Amittha Wickrema, Andrew S. Artz, Koen van Besien

Blood (2011) 118 (24): 6438–6445.

https://doi.org/10.1182/blood-2011-08-372508

Published: 2011

Includes: Supplemental data

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Koen M. Van Besien, MD, Wendy Stock, MD, Elizabeth Shima Rich, MD, PhD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Peter O'Donnell, MD, Justin Kline, MD, Vu H. Nguyen, MD, Paula Del Cerro, RN, Richard A. Larson, MD, Andrew Artz, MD MS

Blood (2011) 118 (21): 1948.

https://doi.org/10.1182/blood.V118.21.1948.1948

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Hongtao Liu, MD, PhD, Elizabeth Shima Rich, MD, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, M.D., Susana Marino, M.D., Justin Kline, MD, Vu H. Nguyen, MD, John M Cunningham, MD, Richard A. Larson, MD, Paula Del Cerro, RN, Linda Schroeder, RN, Lisa Pape, RN, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD MS, Koen M. Van Besien, MD

Blood (2011) 118 (21): 830.

https://doi.org/10.1182/blood.V118.21.830.830

Published: 2011

Journal Articles

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Koen van Besien, MD, Justin Kline, Lucy A Godley, MD, PhD, Richard A. Larson, MD, Vu H. Nguyen, MD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Wendy Stock, MD, Amittha Wickrema, PhD, Scott Allen, BA, Paula del Cerro, Sarah Horowitz, Lisa Pape, RN, Linda Schroeder, RN, Andrew Artz, MD, MS

Blood (2009) 114 (22): 197.

https://doi.org/10.1182/blood.V114.22.197.197

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, Ph.D., Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, MD, Justin Kline, MD, Vu H. Nguyen, MD, Guadalupe Martinez, BS, Paula del Cerro, RN, Lisa Pape, RN, Linda Schroeder, RN, Scott Allen, BA, Sarah Horowitz, BA, John Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Amittha Wickrema, PhD, Koen van Besien, MD

Blood (2009) 114 (22): 3378.

https://doi.org/10.1182/blood.V114.22.3378.3378

Published: 2009

Journal Articles

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, PhD, Amittha Wickrema, PhD, Loren Joseph, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Justin Kline, MD, Paula del Cerro, RN, John M Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Koen van Besien, MD

Blood (2008) 112 (11): 3015.

https://doi.org/10.1182/blood.V112.11.3015.3015

Published: 2008

Journal Articles

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Koen W. van Besien, MD, Andrew Artz, MD, Sonali Smith, MD, Elizabeth Rich, MD, Lucy Godley, MD, PhD, Demetria Jones, Paula Del Cerro, RN, Diane Switzer, RN, Brendan Casey, Olatoyosi Odenike, MD, Michael Thirman, MD, Chris Daugherty, MD, Todd M. Zimmerman, MD, Richard Larson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 2321.

https://doi.org/10.1182/blood.V104.11.2321.2321

Published: 2004

NARROW

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Email alerts

ASH Publications

American Society of Hematology

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only